Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS”…
Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period…